Trials / Completed
CompletedNCT03151551
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 566 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Adalimumab | Administered SC |
Timeline
- Start date
- 2017-08-24
- Primary completion
- 2018-11-15
- Completion
- 2019-09-04
- First posted
- 2017-05-12
- Last updated
- 2020-11-03
- Results posted
- 2019-04-02
Locations
131 sites across 22 countries: Argentina, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Mexico, Netherlands, Poland, South Africa, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03151551. Inclusion in this directory is not an endorsement.